CASUS vs. APACHE II in Predicting Mortality After Coronary Artery Bypass Grafting (CASUS)
The Value of CASUS vs. APACHE II in Predicting Mortality Among Patients Undergoing Coronary Artery Bypass Grafting
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey
- Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
-
Istanbul, Turkey
- Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital in Turkey
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Undergoing coronary artery bypass grafting
- Over 18 years of age
- Staying at least 24 hours in the cardiac intensive care unit
Exclusion Criteria:
- Emergency surgery
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality at 7 days
Time Frame: 7 days
|
Mortality in the first 7 days after surgery
|
7 days
|
|
Mortality at 30 days
Time Frame: 30 days
|
Mortality in the first 30 days after surgery
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of stay in the cardiac intensive care unit
Time Frame: Up to 3 months (Through study completion)
|
Only the length of the initial stay in the cardiac intensive care unit up to 3 months
|
Up to 3 months (Through study completion)
|
|
Length of the stay in the hospital
Time Frame: Up to 3 months (Through study completion)
|
It includes the period from surgery to discharge
|
Up to 3 months (Through study completion)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Nihan YAPICI, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery TRH
- Principal Investigator: Sümeyye UĞUR, Haydarpasa Numune Training and Research Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SU2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mortality
-
NCT06155981Active, not recruiting
-
NCT04032288Completed
-
NCT07508423Not yet recruiting
-
NCT06675071Not yet recruiting
-
NCT07188636Completed
-
NCT05016895Completed
-
NCT03682653Completed
Clinical Trials on Cardiac surgery score and APACHE II scoring
-
NCT06999291Not yet recruitingAnti-Mullerian Hormone Deficiency
-
NCT02828761Withdrawn
-
NCT07298577Enrolling by invitationLiver Cirrhosis | Carcinoma, Hepatocellular | Hepatitis C, Chronic | Hepatitis B, Chronic
-
NCT05312684Not yet recruiting
-
NCT04556188RecruitingRheumatic Heart Disease | Anticoagulant Adverse Reaction
-
NCT01393418CompletedAcute Kidney Injury | Erythropoietin | Renal Biomarker
-
NCT01149837CompletedHuman T-Lymphotrophic Virus Type I and/or Type II
-
NCT06756815CompletedSports Physical Therapy